Stock Taper
SCREENER
COMPARE ANY 2 STOCKS
Pricing
Log In
SIGN UP
EARNINGS CALL ARCHIVE
4 CALLS ON FILE
LGND
— Ligand Pharmaceuticals Incorporated
NASDAQ
FULL STOCK PAGE →
Q4 2025 Earnings Call Summary
FEB 26, 2026
REVENUE
$59.7M
-48.3%
NET MARGIN
75.1%
-26.5 PTS
EPS
$2.27
-62.1%
FREE CASH FLOW
$45.8M
+250.6%
No summary has been written for this call yet.
← NEWER CALL
CALL 3 OF 4
OLDER CALL →